Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
23
1

Year Published

2003
2003
2016
2016

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 27 publications
(25 citation statements)
references
References 41 publications
1
23
1
Order By: Relevance
“…In renal failure, reduced renal production of 1,25(OH) 2 D 3 and subsequently reduced intestinal calcium absorption, together with phosphate retention, drive the development of sHPT. There is firm evidence of increased parathyroid cell proliferation in clinical ( (20)) and experimental uremia. ( (15)) However, because of the complex changes in mineral homeostasis found in renal failure, it is difficult to determine the role of isolated factors in the development of parathyroid hyperplasia. Treatment with active vitamin D analogs has beneficial effects on sHPT in patients with renal failure ( (21,22)) and in experimental models of renal failure. ( (15)) In addition, calcimimetic drugs (i.e., low molecular weight activators of the CaSR) have been shown to prevent parathyroid gland hyperplasia in experimental renal failure ( (23)) and in patients with renal failure, ( (24)) suggesting that signaling through the CaSR also has positive therapeutic effects in sHPT.…”
Section: Introductionmentioning
confidence: 99%
“…In renal failure, reduced renal production of 1,25(OH) 2 D 3 and subsequently reduced intestinal calcium absorption, together with phosphate retention, drive the development of sHPT. There is firm evidence of increased parathyroid cell proliferation in clinical ( (20)) and experimental uremia. ( (15)) However, because of the complex changes in mineral homeostasis found in renal failure, it is difficult to determine the role of isolated factors in the development of parathyroid hyperplasia. Treatment with active vitamin D analogs has beneficial effects on sHPT in patients with renal failure ( (21,22)) and in experimental models of renal failure. ( (15)) In addition, calcimimetic drugs (i.e., low molecular weight activators of the CaSR) have been shown to prevent parathyroid gland hyperplasia in experimental renal failure ( (23)) and in patients with renal failure, ( (24)) suggesting that signaling through the CaSR also has positive therapeutic effects in sHPT.…”
Section: Introductionmentioning
confidence: 99%
“…Numerous studies have shown that SHPT patients exhibit signs of hyperplasia very early, first diffuse, and later nodular hyperplasia [10]. Homogeneous echoes and smaller enlargement were often found in diffuse hyperplasia with less vascularity which can apply the calcitriol [13] to inhibit the secretion of PTH.…”
Section: Discussionmentioning
confidence: 99%
“…Because the size of parathyroid glands is known to be correlated with the severity of SHPT and there is little doubt that in glands larger than 0.5 cm 3 , nodular hyperplasia probably exists [10], we also divided the 42 patients into two groups (volume < 0.5 cm 3 and volume ≥ 0.5 cm 3 ) and examined the relationship between the size of glands and the enhancing model of CEUS. PTG volume was calculated according to the formula V = ( a × b × c ) × Π/6.…”
Section: Methodsmentioning
confidence: 99%
“…If parathyroid glands continue to secrete much more PTH than normal, parathyroid hyperplasia as well as hypertrophy develops unavoidably. Then, it eventually progresses to nodular hyperplasia that cannot be controlled by medical therapy 5 . Thus, it is mandatory to correct the skeletal resistance to PTH for optimal and balanced management of both bone and parathyroid function.…”
Section: Introductionmentioning
confidence: 99%